Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind induction study of oral TAK-279 in moderately to severely active Crohn's disease
jRCT2051240050Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of zasocitinib in Crohn's disease (4 arms), sponsored by Takeda. Primary endpoint: Endoscopic response at Week 12 (SES-CD). Started Mar 2024; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2051240050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240050.